Lung cancer in never smokers-the East Asian experience

about

Lung cancer in never smokers-the East Asian experience

Item

http://www.wikidata.org/entity/Q58804388

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Lung cancer in never smokers-the East Asian experience

@en

Lung cancer in never smokers-the East Asian experience

@nl

type

Item

label

Lung cancer in never smokers-the East Asian experience

@en

Lung cancer in never smokers-the East Asian experience

@nl

prefLabel

Lung cancer in never smokers-the East Asian experience

@en

Lung cancer in never smokers-the East Asian experience

@nl

P1476

Lung cancer in never smokers-the East Asian experience

@en

P2093

Caicun Zhou

http://www.w3.org/2001/XMLSchema#string

Fei Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Increased risk of cancer among relatives of patients with lung cancer in China

Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

ROS1 rearrangements define a unique molecular class of lung cancers.

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

P304

450-463

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/TLCR.2018.05.14

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30225210

http://www.w3.org/2001/XMLSchema#string

P932

6131183

http://www.w3.org/2001/XMLSchema#string